PubMed | National University of Malaysia, Wayne State University, Dr Hari Singh Gour University and Adina Institute of Pharmaceutical science
Type: | Journal: Colloids and surfaces. B, Biointerfaces | Year: 2016
The study was intended to develop a new intra-gastric floating in situ microballoons system for controlled delivery of rabeprazole sodium and amoxicillin trihydrate for the treatment of peptic ulcer disease. Eudragit S-100 and hydroxypropyl methyl cellulose based low density microballoons systems were fabricated by employing varying concentrations of Eudragit S-100 and hydroxypropyl methyl cellulose, to which varying concentrations of drug was added, and formulated by stirring at various speed and time to optimize the process and formulation variable. The formulation variables like concentration and ratio of polymers significantly affected the in vitro drug release from the prepared floating device. The validation of the gastro-retentive potential of the prepared microballoons was carried out in rabbits by orally administration of microballoons formulation containing radio opaque material. The developed formulations showed improved buoyancy and lower ulcer index as compared to that seen with plain drugs. Ulcer protective efficacies were confirmed in ulcer-bearing mouse model. In conclusion, greater compatibility, higher gastro-retention and higher anti-ulcer activity of the presently fabricated formulations to improve potential of formulation for redefining ulcer treatment are presented here. These learning exposed a targeted and sustained drug delivery potential of prepared microballoons in gastric region for ulcer therapeutic intervention as corroborated by in vitro and in vivo findings and, thus, deserves further attention for improved ulcer treatment.
PubMed | International Medical University, National University of Malaysia, Wayne State University, Nirma University and Adina Institute of Pharmaceutical science
Type: Journal Article | Journal: Journal of biomaterials science. Polymer edition | Year: 2016
Worldwide, the cancer appeared as one of the most leading cause of morbidity and mortality. Among the various cancer types, brain tumors are most life threatening with low survival rate. Every year approximately 238,000 new cases of brain and other central nervous system tumors are diagnosed. The dendrimeric approaches have a huge potential for diagnosis and treatment of brain tumor with targeting abilities of molecular cargoes to the tumor sites and the efficiency of crossing the blood brain barrier and penetration to brain after systemic administration. The various generations of dendrimers have been designed as novel targeted drug delivery tools for new therapies including sustained drug release, gene therapy, and antiangiogenic activities. At present era, various types of dendrimers like PAMAM, PPI, and PLL dendrimers validated them as milestones for the treatment and diagnosis of brain tumor as well as other cancers. This review highlights the recent research, opportunities, advantages, and challenges involved in development of novel dendrimeric complex for the therapy of brain tumor.
PubMed | Wayne State University and Adina Institute of Pharmaceutical science
Type: Journal Article | Journal: Drug discovery today | Year: 2016
Despite low prevalence, brain tumors are one of the most lethal forms of cancer. Unfortunately the blood-brain barrier (BBB), a highly regulated, well coordinated and efficient barrier, checks the permeation of most of the drugs across it. Hence, crossing this barrier is one of the most significant challenges in the development of efficient central nervous system therapeutics. Surface-engineered dendrimers improve biocompatibility, drug-release kinetics and aptitude to target the BBB and/or tumors and facilitate transportation of anticancer bioactives across the BBB. This review sheds light on different aspects of brain tumors and dendrimers based on different approaches for treatment including recent research, opportunities and challenges encountered in development of novel and efficient dendrimer-based therapeutics for the treatment of brain tumors.
Singh Bahia M.,Punjabi University |
Kumar Katare Y.,Radharaman Institute of Pharmaceutical science |
Silakari O.,Punjabi University |
Vyas B.,Punjabi University |
Silakari P.,Adina institute of Pharmaceutical science
Medicinal Research Reviews | Year: 2014
Cyclooxygenases (COX-1 and COX-2) catalyze the conversion of arachidonic acid (AA) into PGH2 that is further metabolized by terminal prostaglandin (PG) synthases into biologically active PGs, for example, prostaglandin E2 (PGE2), prostacyclin I2 (PGI2), thromboxane A2 (TXA2), prostaglandin D2 (PGD2), and prostaglandin F2 alpha (PGF2α). Among them, PGE2 is a widely distributed PG in the human body, and an important mediator of inflammatory processes. The successful modulation of this PG provides a beneficial strategy for the potential anti-inflammatory therapy. For instance, nonsteroidal anti-inflammatory agents (NSAIDs), both classical nonselective (cNSAIDs) and the selective COX-2 inhibitors (coxibs) attenuate the generation of PGH2 from AA that in turn reduces the synthesis of PGE2 and modifies the inflammatory conditions. However, the long-term use of these agents causes severe side effects due to the nonselective inhibition of other PGs, such as PGI2 and TXA2, etc. Microsomal prostaglandin E2 synthase-1 (mPGES-1), a downstream PG synthase, specifically catalyzes the biosynthesis of COX-2-derived PGE2 from PGH2, and describes itself as a valuable therapeutic target for the treatment of acute and chronic inflammatory disease conditions. Therefore, the small molecule inhibitors of mPGES-1 would serve as a beneficial anti-inflammatory therapy, with reduced side effects that are usually associated with the nonselective inhibition of PG biosynthesis. © 2014 Wiley Periodicals, Inc.
Mehta N.,Punjabi University |
Kaur M.,Punjabi University |
Singh M.,Punjabi University |
Chand S.,Punjabi University |
And 4 more authors.
Bioorganic and Medicinal Chemistry | Year: 2014
Purinergic receptors, also known as purinoceptors, are ligand gated membrane ion channels involved in many cellular functions. Among all identified purinergic receptors, P2X7 subform is unique since it induces the caspase activity, cytokine secretion, and apoptosis. The distribution of P2X7 receptors, and the need of high concentration of ATP required to activate this receptor exhibited its ability to function as 'danger' sensor associated with tissue inflammation and damage. Further, the modulation of other signalling pathways associated with P2X7 has also been proposed to play an important role in the control of macrophage functions and inflammatory responses, especially towards lipopolysaccharides. Experimentally, researchers have also observed the decreased severity of inflammatory responses in P2X 7 receptor expressing gene (P2RX7) knockout (KO) phenotypes. Therefore, newly developed potent antagonists of P2X 7 receptor would serve as novel therapeutic agents to combat various inflammatory conditions. In this review article, we tried to explore various aspects of P2X7 receptors including therapeutic potential, and recent discoveries and developments of P2X7 receptor antagonists. © 2013 Published by Elsevier Ltd. All rights reserved.
Mishra D.,ADINA Institute of Pharmaceutical science |
Jain N.,ADINA Institute of Pharmaceutical science |
Rajoriya V.,ADINA Institute of Pharmaceutical science |
Jain A.K.,ADINA Institute of Pharmaceutical science
Journal of Pharmacy and Pharmacology | Year: 2014
Objective The present study was focused to prepare controlled release glycyrrhizin (GL) conjugated low molecular weight chitosan nanoparticles (CS-NPs) for liver targeting. The hydrophilic antiretroviral drug lamivudine was chosen as a model drug and encapsulated within glycyrrhizin conjugated low molecular weight chitosan nanoparticles (GL-CS-NPs) for liver specificity. Methods First, the low molecular weight chitosan (CS) was synthesized through depolymerization method. The low molecular weight chitosan nanoparticles were prepared by inotropic gelation method. Then glycyrrhizin was conjugated with previously prepared low molecular weight chitosan nanoparticles (CS-NPs) and conjugation was confirmed by Fourier transform infrared (FT-IR) spectroscopy. Key findings The prepared GL-CS-NPs were characterized using dynamic light scattering, transmission electron microscopy and FT-IR. The encapsulation efficiency and in-vitro drug release behaviour of drug-loaded GL-CS-NPs were studied using ultra violet spectroscopy and high performance liquid chromatographic methods. Release of lamivudine from the nanoparticles exhibited a biphasic pattern, initial burst release and consequently sustained release. In-vivo biodistribution study suggested the target ability of GL-CS-NPs is better and haematological study shows decline of the tissue damage in comparison with plain drug solution. Conclusion The experimental results show that the glycyrrhizin conjugated LMWC nanoparticles may be used as a potential drug delivery system with hepatocyte-targeting characteristics. © 2014 Royal Pharmaceutical Society.
Modi A.,ADINA Institute of Pharmaceutical science |
Kumar V.,Nirma University
Asian Pacific Journal of Tropical Disease | Year: 2014
Luffa echinata Roxb. (Cucurbitaceae) is a spreading climbing herb of tremendous medicinal importance, distributed throughout Pakistan, India, Bangladesh and Northern Tropical Africa. Traditionally various parts of the plant are being used for the treatment of different ailments such as jaundice, intestinal colic, enlargement of liver and spleen, leprosy, diabetes, bronchitis, nephritis, rheumatism, cirrhosis, dropsy, anthelmintic, stomach ache, snake bite, dog bite, fever, diarrohea and hemorrhoid disorder. The plant also possesses antioxidant, analgesic, anti-inflammatory, antidepressant, anxiolytic, antiepileptic, hepatoprotective, antibacterial, antifungal, antiulcer and anticancer activity. Research has been carried out using different techniques to support most of these claims. This review is an attempt to compile an up-to-date data on its ethanomedicinal, phytochemical and pharmacological perspective. © 2014 Asian Pacific Tropical Medicine Press.
Modi A.,Adina Institute of Pharmaceutical science |
Jain S.,Adina Institute of Pharmaceutical science |
Kumar V.,Nirma University
Asian Pacific Journal of Tropical Disease | Year: 2014
Zizyphus xylopyrus (Retz.) Willd (Rhamnaceae) is an ever-green shrub of tremendous medicinal importance, distributed throughout the North-Western India, Pakistan, and China. Various parts of plant are used in Ayurvedic and other folk medicine for the treatment of different ailments such as obesity, diabetes, snake bite, fever, diarrhoea, insomnia and digestive disorders. The plant also possesses antisteroidogenic, anticonvulsent, antinociceptive, antiinflammatory, antidepressant, antidiarroheal and wound healing activity. Research has been carried out using different techniques to support most of these claims. This review is an attempt to compile an up-to-date on its folkloric or traditional uses, phytochemical as well as pharmacological properties of Zizyphus xylopyrus. © 2014 Asian Pacific Tropical Medicine Press.
Jain A.,Adina Institute of Pharmaceutical science |
Jain P.,Adina Institute of Pharmaceutical science |
Kurmi J.,Adina Institute of Pharmaceutical science |
Jain D.,Adina Institute of Pharmaceutical science |
And 5 more authors.
Critical Reviews in Therapeutic Drug Carrier Systems | Year: 2014
Skin is the largest and easily accessible organ of the body and therefore can be extensively used as a prominent route of delivery for local and systemic effects. Though it presents a multifunctional barrier between body and surrounding particles, there are chances to deliver therapeutic nanocarrier, particularly in diseased skin. Both for dermal and transdermal drug delivery, the horny layer, i.e., the uppermost layer of the skin serve as the most resistant layer to be crossed and for this purpose, different perforation techniques are used that relatively widen the skin opening and allow the passage of drug (≤ 10 mg) and micromolecules, but this amateur disruption of the skin can be avoided in order to preserve this barrier against cutaneous microbiota by using deformable nanocarriers. In this review, we discuss the nanosized aggregates and microneedle technology for the advanced delivery of vaccines, protein, peptides, nucleic acid, and hormone across the skin. © 2014 Begell House, Inc.
PubMed | Nirma University and ADINA Institute of Pharmaceutical science
Type: Journal Article | Journal: Chinese journal of natural medicines | Year: 2016
Delonix regia (Bojer ex Hook) Raffin (Fabaceae), also known as flame of forest, is a semi-deciduous tree, distributed throughout Madagascar, India, Africa, and Northern Australia. Various parts of the plant are traditionally used for the treatment of different ailments such as inflammation, rheumatism, bronchitis, diabetes, anemia, fever, gynecological disorders, and pneumonia. The plant possess antioxidant, hepatoprotective, gastroprotective, wound healing, antiarthritic, larvicidal, antimalarial, antiemetic, antibacterial, antifungal, antiinflammatory, analgesic, antidiarrhoeal, antiheamolytic, diuretic, and anthelmintic activities. This review is an up-to-date compilation on its traditional uses in context to phytochemical and pharmacological perspectives.